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A B S T R A C TObjective: To estimate the cost of psychotropic drugs and its impact
on the Brazilian family budget in 2003 and 2009 comparatively.
Methods: This study had a cross-sectional design. Data were obtained
from the Family Budget Surveys conducted in 2003 and 2009, includ-
ing interviews in 48,470 and 55,970 homes of all Brazilian regions,
respectively. The main measures are prevalence of psychotropic drug
acquisition, monetary and nonmonetary expenses with psychotropic
drugs, total spending on drugs, spending on health, total household
spending, and estimated mean monthly household income. All
incomes and expenses from the 2003 survey were adjusted by
inﬂation. Results: There was a reduction in the prevalence of psycho-
tropic drug acquisition by Brazilian households from 13.0% in 2003 tosee front matter Copyright & 2013, International S
r Inc.
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Street, 556/304, Porto Alegre, RS 90130-151, Brazil11.2% in 2009. The mean monthly household spending on psycho-
tropic drugs, however, rose from R $54.38 in 2003 to R $78.73 in 2009.
The percentage of spending on psychotropic drugs from the expenses
with health increased 27%. Conclusions: The increase in spending on
psychotropic drugs can be due to a rise in their prices, the acquisition
of more modern or more expensive drugs, or the increase in the
number of drugs used. Proportionally, spending on psychotropic drugs
grew more than did spending on health by Brazilian families.
Keywords: Brazil, income, psychotropic drugs.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
For many decades, there have been controversies about the extent
of prescription and use of psychotropic drugs, including their cost
[1–4]. In the United States, in the last two decades, the increase in
spending on psychotropic drug acquisition was higher than the
increase in spending on other types of drugs [5,6]. In addition, in
this same country, between 1986 and 2003, there was a growth in
spending on prescribed psychotropic drugs from US $2.2 million
to US $23.6 million [7]. During this period, the pharmaceutical
industry grew and launched new antidepressants and antipsy-
chotic drugs, increasing the variety of recommendations of exist-
ing drugs [8]. Between 1998 and 2007, spending on mental health
remained relatively stable in the United States—US $15.4 million
in 1998 and US $16 million in 2007—although spending on
psychotherapy decreased from US $10.9 million in 1998 to US
$7.2 million in 2007 [9]. These data indicate an increase in the
proportion of spending on mental health drugs [9].
Since 1998, in the United States, the expenses paid by patients
to treat mental disorders have risen more than 10% per year,
surpassing the health spending growth index as a whole [7]. In
Brazil, the current public policies on mental health and the
change in the hospital- and hospitalization-oriented approach tohealth care cause the family to become the main co-responsible
participant in patient care. Thus, patients are provided medical
care as needed, on an outpatient care basis, staying with their
families [10]. Perhaps for this reason, expenses on mental health
treatment are frequently paid by the family because these are not
usually covered by health plans or the government [11].
Brazil is a country of great contrasts of geographic distribution
and social indicators. All health services provided by the federal,
state, and municipal governments are part of a public system
known as the Uniﬁed Health System. The Brazilian Policy on
Mental Health is essentially based on the Declaration of Caracas
[12]. According to estimates from the World Health Organization
[13], approximately 7.6% of the gross domestic product would be
allocated for health in Brazil, of which 58.4% (or 4.44% of the gross
national product) would be private spending, with the greatest
portion being direct spending of families (nearly 70%) [13].
Economic aspects of psychotropic drugs have already been
studied in countries such as Canada and the United States [9,14–
17], although information of this nature is largely unknown in
Brazil. An important source of data for studies on health spend-
ing in Brazil is the Family Budget Survey (FBS) of the Brazilian
Institute of Geography and Statistics. The FBS investigates the
structure of household spending and income in detail, enablingociety for Pharmacoeconomics and Outcomes Research (ISPOR).
o conﬂicts of interest with regard to the content of this article.
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Table 1 – Characteristics of homes from the Family Budget Survey (FBS).
n (%)
2003 FBS 2009 FBS
Region
Northeastern 3,145,614 (6.5) 3,923,041 (6.8)
Northern 12,195,305 (25.2) 15,057,555 (26.1)
Southeastern 21,825,724 (45.1) 25,442,075 (44.1)
Southern 7,743,051 (16.0) 8,884,534 (15.4)
Center-West 3,484,373 (7.2) 4,384,576 (7.6)
Total 48,394,067 (100.0) 57,691,781 (100.0)
Area
Urban 40,989,775 (84.7) 48,691,863 (84.4)
Rural 7,404,292 (15.3) 8,999,918 (15.6)
Total 48,394,067 (100.0) 57,691,781 (100.0)
Number of residents
1 4,887,801 (10.1) 6,865,322 (11.9)
From 2 to 4 30,778,627 (63.6) 39,576,562 (68.6)
From 5 to 8 11,856,546 (24.5) 10,672,979 (18.5)
9 or more 871,093 (1.8) 576,918 (1.0)
Total 48,394,067 (100.0) 57,691,781 (100.0)
Property status
Property is owned and paid 31,891,690 (65.9) 39,230,411 (68.0)
Other status 16,502,377 (34.1) 18,461,370 (32.0)
Total 48,394,067 (100.0) 57,691,781 (100.0)
Number of rooms
Up to 4 12,824,428 (26.5) 13,038,343 (22.6)
From 5 to 7 27,052,283 (55.9) 33,345,849 (57.8)
8 or more 8,517,356 (17.6) 11,307,589 (19.6)
Total 48,394,067 (100.0) 57,691,781 (100.0)
Number of bedrooms
1 16,308,801 (33.7) 19,845,973 (34.4)
2 20,615,872 (42.6) 24,980,541 (43.3)
3 or more 11,469,394 (23.7) 12,865,267 (22.3)
Total 48,394,067 (100.0) 57,691,781 (100.0)
Number of bathrooms
None or 1 38,666,860 (79.9) 43,499,603 (75.4)
2 or more 9,727,207 (20.1) 14,192,178 (24.6)
Total 48,394,067 (100.0) 57,691,781 (100.0)
Monthly spending on psychotropic drugs (US $)
0.00 42,102,838 (87.0) 51,230,302 (88.8)
From 0.01 to 12.99 3,290,797 (6.8) 2,711,514 (4.7)
From 13.00 to 42.99 2,177,733 (4.5) 2,538,438 (4.4)
From 43.00 to 210.00 774,305 (1.6) 1,153,836 (2.0)
Higher than 210.00 48,394 (0.1) 57,691 (0.1)
Total 48,394,067 (100.0) 57,691,781 (100.0)
Total household income (US $)
Lower quintile Up to 272.08 Up to 333.49
Lower middle quintile From 272.09 to 454.26 From 333.50 to 536.11
Middle quintile From 454.27 to 747.98 From 536.12 to 846.44
Upper middle quintile From 747.99 to 1,406.48 From 846.45 to 1,500.84
Upper quintile From 1,406.49 to 166,359.19 From 1,500.85 to 49,251.76
BCPI, Brazilian Consumer Price Index.
 The values referring to 2003 were adjusted by the accumulated inﬂation until 2009 by using the BCPI.
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spending on health, among other aspects [18]. Until this moment,
ﬁve studies of this size have been conducted in Brazil. The
present study analyzed data from the 2003 and 2009 FBSs.
The aim of the present study was to estimate the cost of the
acquisition of psychotropic drugs and its impact on the budget of
Brazilian families, in 2003 and 2009 comparatively, with the
purpose of observing and understanding the changes in spending
on psychotropic drugs.Methods
The data used in this study were obtained from the 2002-2003
and 2008-2009 FBSs conducted by the Brazilian Institute of
Geography and Statistics. The 2002-2003 FBS was con-
ducted between July 2002 and June 2003 [19], while the 2008-
2009 FBS was conducted between May 2008 and May 2009
[18].
Table 2 – Mean monthly household spending on psychotropic drugs by geographical region and income in
Brazil in 2003 and 2009.
2003 (n ¼ 6,286,832) 2009 (n ¼ 6,445,106)
Monthly mean (US $)† 95% CI Monthly mean (US $) 95% CI
Brazil 22.85 21.32–24.38 33.08 27.65–38.51
Region
Northern 12.92 11.35–14.48 24.78 20.59–28.97
Northeastern 15.07 13.65–16.49 22.93 19.94–25.92
Southeastern 25.69 23.84–26.71 37.37 27.19–47.55
Southern 25.09 22.08–28.11 33.26 28.60–37.91
Center-West 25.26 23.02–27.09 31.51 27.42–35.60
Income (in quartiles)
Lower quartile 14.79 13.74–15.42 17.59 15.59–19.59
Lower middle quartile 16.54 14.69–18.45 21.15 19.29–23.00
Upper middle quartile 18.48 16.76–20.21 24.76 22.55–26.98
Upper quartile 31.08 27.79–34.39 49.59 36.14–63.04
BCPI, Brazilian Consumer Price Index; CI, conﬁdence interval.
 Number of households that have any expenses with psychotropic drugs.
† Values referring to 2003 were adjusted by the accumulated inﬂation until 2009 by using the BCPI.
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cluster sampling plan was used in both surveys, with a geographic
and statistical stratiﬁcation of the primary sample units—census
tracts—which were selected by simple random sampling in each
stratum. Secondary sample units were the permanent private
homes, also selected by simple random sampling, without
replacement, inside each previously selected census tract [18].
The empty households and collective or temporary homes were
excluded. In 2003, a total of 60,911 homes were selected and of
these, 48,470 were surveyed [19]. In 2009, there were 68,373 homes
selected and of these, 55,970 were surveyed [18].
Each home included in the FBS sample represents a certain
number of permanent private homes in the population from
which this sample was selected. Thus, a certain weight is
associated with each sample home, which is attributed to the
characteristics investigated in this study, enabling estimates of
quantities of interest for the country to be obtained [18,19].
The data collection instruments used were the questionnaires
described in the Brazilian Institute of Geography and Statistics
publications [18,19]. Data were collected through interviews in
the selected homes for nine consecutive days. The FBS inves-
tigates permanent private homes, where, in their turn, there is a
unit of consumption (a single resident or a group of residents
who share the same food source or housing expenses) [18,19].
Data on spending on psychotropic drugs were obtained from
the Pharmaceutical Product Acquisition Table included in the
Questionnaire about Individual Expenses, during the reference
period of 30 days, by adding the expenses with drugs for
“depression” and “the nervous system.” Data on spending on
drugs were obtained by adding the expenses with all classes of
drugs found in the same table. Data on spending on health were
also obtained from the previously described table, apart from the
expenses of the Health Care Service Table, during the reference
period of 90 days. Data on total household spending were
obtained from the sum of all monetary and nonmonetary
expenses studied (both household expenses and individual
expenses added per home). All values were converted into
monthly expenses. This standardization was performed to adjust
the different reference periods for each group of expenses.
The mean monthly household income estimated in the FBS is
composed of monetary income (work incomes, transfers, rent
incomes, and other household incomes) and nonmonetary
income (estimated from the use and consumption of productsacquired through one’s own production, business revenues,
exchanges, and donations, among others) [18,19]. The informa-
tion about expenditures and incomes was declared by the
interviewees. With regard to the information about monetary
and nonmonetary expenses, the FBS attributes different refer-
ence periods: 7 days, 30 days, 90 days, and 12 months—according
to the type of expense—which will be subsequently converted
into annual expenses, adjusted by inﬂation during the period
[18,19]. In this study, all family expenses were calculated as
monthly expenses, following the data on individual expenses
and income. In addition, all incomes and expenses from the 2003
FBS were adjusted by the accumulated inﬂation during the
period, until 2009. The index used was the Brazilian Consumer
Price Index, assessed by the Brazilian Institute of Geography and
Statistics, which is considered to be the country’s ofﬁcial inﬂation
index by the Central Bank [20]. Nominally, the inﬂation accumu-
lated between January 2003 and January 2009 was 42.5%. This
procedure was performed to adjust the effects of inﬂation and,
consequently, enable a direct comparison of values between the
two periods analyzed.
The analysis was performed according to a complex sampling
plan, where the census tracts are the clusters and the strata are
those previously deﬁned by the Brazilian Institute of Geography
and Statistics (urban area of the capital city, other metropolitan
areas, other state areas, and rural area), although not all Brazilian
states have all strata. The means and percentages were calcu-
lated; conﬁdence intervals (CIs) of 95% were used to compare the
means obtained. The Predictive Analytics SoftWare 18.0 applica-
tion (formerly known as SPSS Statistics) was used to create the
main databases and to perform the statistical analyses.
Because the present study included secondary data from
studies that had been previously approved by research ethics
committees (on the federal level) and made available online for
public access, the subsequent analysis by local ethics committees
was dismissed and authors were responsible for the conclusions
of their analyses [21].Results
When expanded, the 48,470 homes from the 2003 FBS repre-
sented 48,394,067 homes; likewise, the 55,970 homes from the
2009 FBS were expanded and represented 57,691,781 homes.
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2003 and 2009.
The prevalence of acquisition of psychotropic drugs per
household was 13.0% (95% CI 12.4%–13.6%) in 2003 (n ¼
48,394,067) and 11.2% (95% CI 10.7%–11.7%) in 2009 (n ¼
57,691,781), with a reduction of 14%. In 2003, the sum of all
monthly expenses with psychotropic drugs, adjusted by the
inﬂation, totaled US $103,604,094.00; of this amount, 83.4% was
spent by families (monetary expenses) and the remaining
amount corresponded to nonmonetary expenses (received with-
out expenditure of money). The sum of all monthly expenses
with psychotropic drugs was US $213,212,868.00 in 2009, of which
66.6% was monetarily acquired by Brazilian families.
Table 2 shows the monthly expenses with psychotropic drugs
among the households that acquired any of these drugs, by
region and household income, in 2003 and 2009. Table 3 shows
the mean cost of acquisitions including psychotropic drugs by
household income in Brazil in 2003 and 2009. Both tables indicate
the signiﬁcant increase in spending on psychotropic drugs in all
income strata and in all Brazilian regions from 2003 to 2009. The
northern and southeastern regions showed the highest increase
in mean monthly spending on psychotropic drugs. With regard to
the value of acquisition of psychotropic drugs (Table 3), the
increase observed between these two years is directly propor-
tional to the growth in the income of Brazilian families.
Table 4 shows the percentages of expenses with psychotropic
drugs from the income, total monthly household spending (direct
and indirect costs), monthly spending on health, and monthly
spending on drugs in 2003 and 2009. Based on this table, there
was an increase of 26.5% in the spending on psychotropic drugs
from the monthly household income in Brazil between 2003 and
2009; in contrast, there was an increase of 19.0% from the
monthly household spending between 2003 and 2009. The per-
centage of spending on psychotropic drugs from the monthly
household spending on health and from the spending on drugs
increased 27.0% and 26.7%, respectively, between 2003 and 2009.Discussion
The results obtained show that there was a reduction in the
prevalence of acquisition of psychotropic drugs by Brazilian
households between 2003 and 2009, although the mean monthly
spending on these drugs per household increased in this same
period. In addition, the percentages of spending on psychotropic
drugs from the monthly household income and from the
monthly household spending were higher in 2009 than in 2003.
The main limitation of this study is that the FBS research does
not assess health conditions. It focused on several aspects of
personal/household income and expenditures, including health
spending. Another limitation included the absence of deﬁnitions
of drug names and classes; this prevented the assessment of
direct drug costs and their various formulations. Furthermore,
drug units were not described in the 2009 FBS as they were in the
2003 FBS, which did not enable comparisons per pharmacotech-
nical unit to be made, only per number of acquisitions. However,
samples are representative of the entire country, with detailed
data on all expenses and incomes of the population, which is the
focus of this study.
Brazilian households were mainly concentrated in the south-
eastern region and in urban areas. The majority of families
comprised two to four residents. Approximately two thirds of
the population had their own property, fully paid off, and this
number increased between 2003 and 2009. Most Brazilian homes
had between ﬁve and seven rooms, two of which were bedrooms.
According to the results shown in Table 1, there were no
signiﬁcant changes in the characteristics of Brazilian homes
Table 4 – Percentage of spending on psychotropic drugs from the income and other expenses in 2003 and 2009.
Percentage of spending
on psychotropic drugs
from
Lower quartile
of monthly
income (%)
Lower middle
quartile of monthly
income (%)
Upper middle
quartile of monthly
income (%)
Upper quartile
of monthly
income (%)
Brazil
(%)
2003
Monthly household
income
0.49 0.29 0.32 0.24 0.34
Monthly household
expenses
0.83 0.93 0.80 0.77 0.83
Monthly household
health expenses
3.02 3.03 2.89 2.91 2.96
Monthly household
expenses with drugs
3.11 3.92 4.07 4.78 3.97
2009
Monthly household
income
0.63 0.47 0.40 0.31 0.43
Monthly household
expenses
1.01 1.17 0.98 0.81 0.99
Monthly household
health expenses
3.13 3.81 3.90 4.20 3.76
Monthly household
expenses with drugs
3.77 4.83 5.64 5.89 5.03
BCPI, Brazilian Consumer Price Index.
 Values referring to 2003 were adjusted by the accumulated inﬂation until 2009 by using the BCPI.
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most changed, as it increased between 2003 and 2009, despite the
adjustment by inﬂation. This shows that salaries increased more
than the inﬂation and that, according to the Brazilian Institute of
Geography and Statistics (2010) [18], the number of individuals in
the job market rose 3%.
The prevalence of acquisition of psychotropic drugs had a
reduction of 14% between the years assessed, decreasing from
13.0% to 11.2%. In the 1990s and early 2000s, the prevalence of the
use of psychotropic drugs (especially antidepressants) increased
with time in the populations of North America, Europe, and
Australia [22–28]. The prevalence of the consumption of anxio-
lytics, sedatives, hypnotics, antipsychotics, and antimanics
remained stable in the United States between 1988 and 1994
and between 1999 and 2002 [29]. Researchers observed that the
use of antidepressants and anxiolytics decreased from 2.8% to
1.5% between 2004 and 2005 in 48 American states [30]. In recent
years, there has been stabilization in the prevalence of the use of
psychotropic drugs and a small reduction in the case of anti-
psychotic drugs [31]. In 2010, the Applied Economics Research
Institute published a study that showed that the consumption of
drugs purchased per person in the private health network
decreased from 11.2 to 9.2 units between 1990 and 2009, that is,
a reduction of 19.9% [32].
The Brazilian government covers costs of basic psychotropic
drugs through its Healthcare Program for its citizens. This system
ensures access to basic psychotropic drugs to all people who are
admitted to a psychiatric unit. The drug classes available, how-
ever, are limited to the basic psychotropic drugs, which are
deﬁned in the Essential Drug List. In addition, the supply chain
is not completely reliable in drug distribution. The aforemen-
tioned factors may suggest that some citizens may purchase their
medications [12,32]. The number of individuals who acquired
psychotropic drugs in a nonmonetary way has risen, suggesting
that there has been an increase in equality of access to these
drugs. Such an increase can be a direct reﬂection of public
investments for the access to drugs in Brazil, which is a right of
the citizens.Despite the decrease in the prevalence of acquisition of
psychotropic drugs, spending on such drugs by Brazilian families
has increased, even when values are adjusted by the inﬂation.
Other studies have also found an increase in the cost of
psychotropic drugs for patients [15,33]. Data from 2009 in the
United States revealed that spending on these drugs was higher
than US $380 million [34].
In Brazil, between 2007 and 2010, the most sold psychotropics
were the anxiolytics (clonazepam, bromazepam, and alprazolam),
followed by phenobarbital and carbamazepine [35]. The increase
in the cost of psychotropic drugs can be explained, in Brazil, by
the release of more expensive drugs into the market. As a result,
this contributes to the rise in the price of these drugs [36], and to
the increase in the number of drugs used. Of all studies that
showed an increase in the prevalence and cost of antidepressants,
many reported that one of the causes would be the replacement of
old drugs by selective serotonin reuptake inhibitors and other new
drugs, which usually have a higher cost [24,25,27,28,36]. In the
United States, between 1998 and 2007, spending on antidepres-
sants rose from US $4.59 billion to US $6.60 billion, whereas
spending on psychotropic drugs decreased [33]. In this same
country, it is estimated that US $1.41 billion were spent on
prescribed psychotropic drugs for the elderly and that more than
half would have been paid by patients [15]. In Canada, per-capita
spending on psychotropic drugs increased 106.0% (from US $29 to
US $60) between 1998 and 2004 [17]. In the United States, the
prevalence of drug use did not change between 1998 and 2006,
while the multipharmacy grew [30]. Data show that the percent-
age of prescriptions of two or more psychotropic drugs has
increased from 42.6% to 59.8% in the United States in recent years
[34] because of changes in patients’ characteristics and an
increase in the severity of symptoms [34]. In addition, there was
an increase in the identiﬁcation of psychiatric comorbidities [37].
Mean monthly spending on psychotropic drugs was higher in
the southeastern and southern regions of Brazil. Pharmaceutical
business in different regions, cultural factors, and the greater
number of health services in these places are some of the
characteristics that can explain such differences. The
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per 100,000 inhabitants, respectively, while the center-west
region has 2.5 psychiatrists per 100,000 inhabitants, the north-
eastern region 1.5, and the northern region 0.7 [38]. Despite such
differences in the distribution of psychiatrists, it is believed that
the majority of these drugs are prescribed by physicians of all
specialties. The distribution of acquisitions practically did not
change between 2003 and 2009 in Brazil. The values of acquis-
itions rose in direct proportion to the increase in income stratum:
from 29.4% in the lower income strata to 44.1% in the higher
income strata. According to the presented results, spending on
drugs is always higher among wealthier families in absolute
values, regardless of the type of drug. In the case of psychotropic
drugs, this could be explained by the lack of access to diagnosis
and treatment of poorer individuals or by the abusive use by the
wealthy population that, having resources for such, purchases
these drugs even when there is no clear diagnosis [39]. A
population survey conducted in ﬁve Brazilian states found a
prevalence of 87% in the access to drugs prescribed in the
previous medical consultation [40]. One of the causes for the
poorer population’s lack of access could be the general physi-
cians’ difﬁculty in diagnosing and managing patients with men-
tal and emotional disorders in primary care services [41].
According to Steele et al. [42], the increase in the population’s
purchasing power contributes to the rise in drug consumption. In
Canada, despite the universal health coverage, individuals with a
higher socioeconomic level also receive more psychiatric treat-
ment than do those with a lower level, when equivalent mental
disorders are taken into consideration [41]. It is estimated that in
developing countries, nearly 90% of the patients with mental
disorders do not receive treatment [43], mainly because of the
high cost of prescribed drugs [33,44]. In the city of Porto Alegre,
Southern Brazil, of a sample of 155 individuals, 40% reported that
the cost of treatment for depression is a barrier to this treatment
[44]. In a study conducted in a representative sample of adults in
the United States, 26.0% of the individuals who used antidepres-
sants were not diagnosed with any psychological morbidities [45].
These same individuals frequently obtained the prescription
from a family physician or other physicians who were not
psychiatrists [45].
Between 2003 and 2009, there was an increase in the percent-
age of spending on psychotropic drugs from the income. Accord-
ing to the Brazilian Ministry of Health, 51% of the population—
with an income of up to 4 minimum wages—consume 16% of all
drugs in the market; 34% of them—with an income between 4 and
10 minimum wages—consume 36%; and 15%—with an income of
more than 10 minimum wages—consume 48% [46]. Among
wealthy Brazilian families, 1.7% of their income was spent on
drugs, whereas poorer families spent 12.0% of their families’
income on drugs [39]. Although the expenditure was smaller in
proportion for the wealthier families, they spent nine times more
than did poorer families in absolute monetary value [39].
The percentages of spending on psychotropic drugs from
monthly household expenses and from health expenses of all
income strata increased between the years assessed. This shows
that access to drugs is affected in the poorest segment of the
population because the value of drugs is considered to be one of
the main obstacles to such access [44]. According to the 2002-2003
FBS, household spending on drugs totals nearly 25% of health
expenses [46].
The percentage of spending on psychotropic drugs from the
total expenses with drugs increased 26.7%. In all income strata,
there was a signiﬁcant increase between 2003 and 2009. Spending
on psychotropic drugs rose more than did other expenses,
including health, among Brazilian families. This could reﬂect
the greater use of modern drugs, which have potential advan-
tages of efﬁcacy and safety, especially for the elderly population,and are more expensive, or the increase in the amount of
psychotropic drugs used.Conclusions
One of the forms of inequality present in different societies is the
unequal access to health resources and services. Poorer families
are the ones who spend least with psychotropic drugs in absolute
terms, compared with wealthier families, in addition to propor-
tionately using more of their income to purchase these drugs.
The unequal pattern of spending on psychotropic drugs by
Brazilian families, when ordered by income, has not changed
signiﬁcantly in recent years.
Source of ﬁnancial support: The author Samanta E. Fröhlich
was granted a scholarship by the Coordination for the Improve-
ment of Higher Education Personnel to support her doctoral
degree program in Epidemiology.
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